Biocad has announced the start of patient recruitment for the Phase III clinical trial of BCD-281

Biocad, a member of BIOPROM, announced the launch of patient recruitment for a phase III clinical trial of BCD-281, a biosimilar of ocrelizumab used for multiple sclerosis.

Ocrelizumab is a humanized monoclonal antibody for the treatment of recurrent forms of multiple sclerosis, as well as for the primary progressive type of the disease, according to Biocad.

Research centers are opening in Moscow, St. Petersburg, Chelyabinsk, Kirov, Novosibirsk, Nizhny Novgorod, Rostov-on-Don and other cities.

BCD-281 has previously been confirmed to be biosimilar and to have a comparable safety profile in physico-chemical tests and Phase I clinical trials.

According to experts, more than 100 thousand people live with multiple sclerosis in Russia. For them, access to modern drugs is a key factor in slowing the progression of the disease.

Biocad continues to strengthen its own line of high-tech biologics, shaping the competencies of the Russian biopharma and contributing to the development of the industry.